1182PDA novel affinity-enhanced NY-ESO-1-targeting TCR-redirected T cell transfer exhibited early-onset cytokine release syndrome and subsequent tumour responses in synovial sarcoma patients
ConclusionsThe affinity-enhanced NY-ESO-1/TCR-T cell transfer exhibited early-onset CRS in association with in vivo cell proliferation and sequential tumor responses in the patients with high-NY-ESO-1-expressing synovial sarcoma.Clinical trial identificationNCT02366546.Legal entity responsible for the studyThe authors.FundingJapan Agency for Medical Research and Development.DisclosureAll authors have declared no conflicts of interest.
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research
More News: Actemra | Cancer | Cancer & Oncology | Clinical Trials | Genetics | Legislation | Melanoma | Research | Sarcomas | Skin Cancer | Study | Synovial Sarcoma